Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Preoperative Metformin May Improve Surgical Outcomes

By HospiMedica International staff writers
Posted on 29 Apr 2020
A new study suggests that preoperative metformin may be associated with decreased postoperative mortality and readmission in type 2 diabetes (T2D) patients. More...


Researchers at the University of Pittsburgh School of Medicine (Pitt; PA, USA) and the Veterans Affairs Pittsburgh Healthcare System (PA, USA) conducted a retrospective observational study involving 5,460 patients with T2D who underwent a major surgical procedure at one of 15 community and academic hospitals between 2010 and 2016. The main outcomes and measures were all-cause postoperative mortality, hospital readmission within 90 days of discharge, and preoperative inflammation, with or without preoperative metformin.

The results revealed that preoperative metformin was associated with a 3% 90-day mortality risk in the T2D patients who received preoperative metformin, compared to 5% in those who did not; patients in both groups had the same rate of 30-day mortality (2%). In addition, the 30-day readmission rate was also lower in the preoperative metformin group (11%), than in those without (13%). Preoperative inflammation was also reduced in the metformin group, compared to those without, as measured by mean neutrophil to leukocyte ratio. The study was published on April 8, 2020, in JAMA Surgery.

“This study found an association between metformin prescriptions provided to individuals with type 2 diabetes before a major surgical procedure and reduced risk-adjusted mortality and readmission after the operation,” concluded lead author Katherine Reitz, MD, of the PITT department of surgery, and colleagues, suggesting that “adults with comorbidity have less physiological reserve and an increased rate of postoperative mortality and readmission after the stress of a major surgical intervention.”

Metformin belongs to a class of drugs called biguanides, which inhibit the production of glucose in the liver. In addition to suppressing hepatic glucose production, metformin also increases insulin sensitivity, enhances peripheral glucose uptake, decreases insulin-induced suppression of fatty acid oxidation, and decreases absorption of glucose from the gastrointestinal tract.

Related Links:
University of Pittsburgh School of Medicine
Veterans Affairs Pittsburgh Healthcare System



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.